Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BeiGene In-licenses Rights To LAG-3 mAb from Leads Bio in $772 Million Deal

publication date: Dec 14, 2021

Beijing's BeiGene in-licensed ex-China rights to a LAG-3 immunotherapy developed by Nanjing Leads Biolabs in a $772 million collaboration agreement. BeiGene will have development, manufacturing and commercialization rights to the candidate outside of China. In a Phase I trial, LBL-007 was well tolerated and showed initial signs of activity in patients with advanced solid tumors. LAG-3 is an immune checkpoint receptor expressed on activated T cells that negatively regulates these cells, resulting in tumor immune escape. More details....

Stock Symbol: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital